alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › clinical-trials

clinical-trials

3 studies tagged clinical-trials, dated 2022-03-02 to 2024-04-27. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review 2024-04-27
  2. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials 2023-03-06
  3. Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice 2022-03-02

Studies

3 studies carry this tag.

Date range

2022 to 2024

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Alzheimer's research & therapy 1
  • Neurology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2024-04-27 Biomarkers

    As the field moves towards primary prevention, we expect an increase in the use of fluid-based biomarkers to determine disease modification.

  2. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Neurology 2023-03-06 Biomarkers

    Plasma p-tau181/NfL can potentially be used to monitor large-scale population interventions in CU individuals.

  3. Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2022-03-02 Biomarkers

    Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity.

All topic tags with their study counts